Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AV5080 in patients with influenza
NCT05095545Phase 2Completed
- Sponsor
- Viriom Inc
- Start
- Nov 2017
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AV5080 in influenza (3 arms), sponsored by Viriom Inc. Primary endpoint: Percentage of patients who reported resolution of influenza symptoms within 96 hours from the start of therapy. Started Nov 2017; status: completed.
02
Drugs
AV5080
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05095545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05095545.